Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

221.49
-2.7000-1.20%
Post-market: 215.00-6.4899-2.93%19:34 EST
Volume:962.61K
Turnover:211.20M
Market Cap:13.66B
PE:-48.80
High:224.90
Open:221.83
Low:214.60
Close:224.19
52wk High:242.00
52wk Low:118.03
Shares:61.70M
Float Shares:60.08M
Volume Ratio:1.06
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5384
EPS(LYR):-6.7615
ROE:-818.43%
ROA:-7.69%
PB:-66.09
PE(LYR):-32.76

Loading ...

Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate

Benzinga
·
11 hours ago

ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside

TIPRANKS
·
5 hours ago

Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment

Reuters
·
6 hours ago

Earnings Flash (ASND) Ascendis Pharma Posts Q4 Loss -0.55 Euro, vs. FactSet Est of -0.19 Euro Loss

MT Newswires Live
·
11 hours ago

Ascendis Pharma reports FY 2025 net loss of EUR 228 million, narrowing 40%

Reuters
·
11 hours ago

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

Health Canada genehmigt Yorvipath von Ascendis Pharma für die Behandlung von chronischem Hypoparathyreoidismus

Reuters
·
Feb 07

Ascendis Pharma A/S to Announce Full Year 2025 Financial Results and Business Update

Reuters
·
Feb 05

Ascendis Pharma price target raised to $260 from $246 at BofA

TIPRANKS
·
Jan 30

Ascendis Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 30

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

MT Newswires Live
·
Jan 29

Ascendis Pharma Initiated at Overweight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on Ascendis Pharma With Overweight Rating, $342 Price Target

MT Newswires Live
·
Jan 28

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
Jan 27

Ascendis Pharma rumor highlighted in Betaville blog

TIPRANKS
·
Jan 23

Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Ascendis Pharma (ASND)

TIPRANKS
·
Jan 21

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Jan 21

RBC Raises Price Target on Ascendis Pharma to $250 From $245, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 20

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

TIPRANKS
·
Jan 20

Ascendis Pharma a/S : Leerink Partners Raises Target Price to $290 From $225

THOMSON REUTERS
·
Jan 20